Analysis of REVLIMID in Patients with Non-Del-5Q MDS Demonstrated Improved Health Related Quality of Life Measures

By: via Benzinga
Abstract #116 Celgene Corporation (NASDAQ: CELG) today announced results from a pre-specified secondary endpoint analysis of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.